Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Financing Cash Flow

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$2.74B+59,591%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-32.0%
Insmed logo
InsmedINSM
$27.18M-96.8%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$1.47M+2,821%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+1.1%
Enterprise value$1.4B-3.9%
P/S0.9×—

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%—
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-208893
Line itemFor the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Proceeds from borrowings under the Revolving Credit Facility250,000—
Repayments of borrowings under the Revolving Credit Facility(250,000)—
Payments related to obtaining the Revolving Credit Facility—(3,210)
Net cash provided by financing activities24112,471
Decrease in cash, cash equivalents and restricted cash(336,832)(862,143)
Cash, cash equivalents and restricted cash:
Beginning of period814,4071,118,589
End of period$477,575$256,446

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s financing cash flow?
Sarepta Therapeutics, Inc. (SRPT) reported financing cash flow of $241K in Q1 2026.
How has Sarepta Therapeutics, Inc.'s financing cash flow changed year-over-year?
Sarepta Therapeutics, Inc.'s financing cash flow decreased by 98.1% year-over-year, from $12.47M to $241K.
What is the long-term trend for Sarepta Therapeutics, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s financing cash flow has grown at a -26.0% compound annual growth rate (CAGR), from $561.57M to -$168.34M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Sarepta Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude